Items where authors include "Xu, XL"

Article

McGonagle, D, McInnes, IB, Deodhar, A et al. (10 more authors) (2023) Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR Open Rheumatology, 5 (4). pp. 227-240. ISSN 2578-5745

Orbai, A-M, Coates, LC, Deodhar, A et al. (10 more authors) (2022) Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. The Patient: Patient Centered Outcomes Research, 15 (6). pp. 657-668. ISSN 1178-1653

Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105, Gladman, DD et al. (14 more authors) (2021) Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. The Lancet Rheumatology, 3 (10). e715-e723. ISSN 2665-9913

Mease, PJ, Gladman, DD, Deodhar, A et al. (9 more authors) (2020) Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open, 6 (2). e001217. ISSN 2056-5933

Deodhar, A, Helliwell, PS, Boehncke, W-H et al. (9 more authors) (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet, 395 (10230). pp. 1115-1125. ISSN 0140-6736

Conference or Workshop Item

Behrens, F, Mease, PJ, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo-Controlled Studies. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Orbai, AM, Coates, LC, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 Discover-1 Trial. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Mease, PJ, Foley, P, Reich, K et al. (14 more authors) (2021) Low Incidence of Gastrointestinal-Related and Overall Serious Adverse Events among Guselkumab-Treated Patients: Pooled Analyses of Voyage 1 & 2 and Discover 1 & 2 Through 1-Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Ritchlin, CT, Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (13 more authors) (2021) Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through 1 Year. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Behrens, F, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (8 more authors) (2021) Efficacy of Guselkumab Across Basdai Components in Treating Axial-Related Symptoms of Psoriatic Arthritis: Results from Two Phase-3, Randomized, Placebo-Controlled Studies. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Coates, LC, Ritchlin, CT, Gossec, L et al. (12 more authors) (2021) Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed using Composite Endpoints in Patients with Active Psoriatic Arthritis. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Rahman, P, Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105 et al. (12 more authors) (2021) Integrated Safety Results of Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis through the Placebo-Controlled Periods. In: Twelfth International Congress on Spondyloarthritides, 09-11 Sep 2021, Virtual.

Orbai, AM, Coates, LC, Deodhar, A et al. (8 more authors) (2020) AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1. In: EULAR 2020, 03-06 Jun 2020, Online.

Rahman, P, Ritchlin, CT, Helliwell, P et al. (13 more authors) (2020) FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS. In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Gladman, DD, Poddubnyy, D et al. (13 more authors) (2020) OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. In: EULAR 2020, 03-06 Jun 2020, Online.

Ritchlin, CT, Helliwell, P, Boehncke, WH et al. (8 more authors) (2020) SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED. In: EULAR 2020, 03-06 Jun 2020, Online.

Deodhar, A, Helliwell, P, Boencke, W-H et al. (8 more authors) (2020) GUSELKUMAB, AN ANTI-INTERLEUKIN-23P19-SUBUNIT MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO WERE BIOLOGIC-NAIVE OR PRIOR TNF alpha INHIBITOR-TREATED: WEEK 24 RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. In: 22nd PANLAR Congress, 12-15 Aug 2020, Miami, Florida, USA.

Deodhar, A, Helliwell, P, Boehncke, W-H et al. (8 more authors) (2020) P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. In: British Society for Rheumatology Annual Conference, 20-22 Apr 2020, Online.

Deodhar, A, Kirkham, B, Rahman, P et al. (6 more authors) (2020) P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.

Proceedings Paper

Helliwell, P, Deodhar, A, Gottlieb, AB et al. (7 more authors) (2019) Comparing Composite Measures of Disease Activity in Psoriatic Arthritis: Results From a Randomized Phase 2 Trial with Guselkumab. In: Annals of the Rheumatic Diseases. EULAR 2019: Annual European Congress of Rheumatology, 12-15 Jun 2019, Madrid, Spain. BMJ Publishing Group , p. 1843.

Gladman, DD, Boehncke, W-H, Gottlieb, AB et al. (8 more authors) (2018) The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

Helliwell, P, Gottlieb, AB, Deodhar, AA et al. (8 more authors) (2018) The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .